Fierce Pharma March 7, 2024
With the swelling popularity of Eli Lilly’s diabetes med Mounjaro and its weight loss counterpart Zepbound, unauthorized copycats continue to emerge, posing a growing safety risk.
In an updated open letter, the company expressed “deep concern” over sham products that falsely claim to be real, FDA-approved medicines.
Lilly reiterated that it does not sell any product referred to as simply tirzepatide, the active ingredient in its Mounjaro and Zepbound. The company doesn’t provide the ingredient to any compounding pharmacies either.
The drugmaker has discovered fake and compounded versions of the drugs that contain “bacteria, high impurity levels, different chemical structures” and other concerning features that differentiate them from the company’s medicines, according to the letter.
In “at least one” case,...
Today's Sponsors
Today's Sponsor